Welcome to the Breakthrough Era! Join Us at FDA/CMS Summit to Explore the Emerging Public Policy Climate for Highly Effective Targeted Therapies
(firmenpresse) - WASHINGTON, DC -- (Marketwired) -- 10/17/13 -- FDA's new "Breakthrough Therapy" designation is off to a fast start, with more than 25 products deemed worthy of the status in the first year since the program took effect. FDA and sponsors both seem energized and excited by the new pathway.
But there are many more important questions in the background: What will the new designation really mean for drug development? Will the new pathway (and other changes in the regulatory process) mean more new therapies reach the market more quickly? Will those therapies succeed -- medically and commercially -- once they get there? And will the "Breakthrough" focus mean other products get left behind, languishing for lack of regulatory attention and/or management support?
Join us at , December 11-12 in Washington, DC to explore these questions and many other cutting edge topics in biopharma policy. This year's conference will explore all aspects of the emerging new regulatory models, including conversations with key FDA officials and industry stakeholders on their experience thus far, as well as broader discussions of the role of "Breakthrough" in shaping drug development and reimbursement policies.
Among the speakers and topics on the jam packed two-day agenda are:
by Janet Woodcock, MD, Director of Center For Drug Evaluation & Research at Food and Drug Administration (FDA)
with Jonathan Blum, Deputy Administrator and Center for Medicare Director at Centers for Medicare & Medicaid Services (CMS)
with John Jenkins, MD, Director of Office of New Drugs at Food and Drug Administration (FDA); Gerald Dal Pan, MD, Director of Office of Surveillance & Epidemiology at Food and Drug Administration (FDA); Richard Pops, CEO at Alkermes; and Paul Seligman, MD, Executive Director of Regulatory Affairs at Amgen Global Government Affairs; and Wendy R. Sanhai, PhD, Senior Director, Regulatory Policy and Advocacy at GlaxoSmithKline
with Louis Jacques, MD, Director of Coverage & Analysis Group Office of Clinical Standards and Quality at Centers for Medicare & Medicaid Services (CMS) and Tamara Syrek Jensen, JD, Deputy Director of Coverage & Analysis Group Office of Clinical Standards and Quality at Centers for Medicare & Medicaid Services (CMS)
with Francois Nader, MD, Chairman, President and CEO at NPS Pharmaceuticals; Diane Dorman, Vice President for Public Policy at National Organization for Rare Disorders; Gayatri Rao, MD, Director of Office of Orphan Products Development at Food and Drug Administration (FDA); and Chris Garabedian, President & CEO at Sarepta Therapeutics
with Jeff Allen, PhD, Executive Director at Friends of Cancer Research; Sandra Rattray, MD, VP and Head of Global Regulatory Affairs, Oncology at Johnson & Johnson; Richard Pazdur, MD, Director of Office of Hematology and Oncology Products, Center for Drug Evaluation & Research at Food and Drug Administration (FDA); Victor Sandor, MD, CM, Group Vice President, Clinical Development at Incyte Corporation; and Joseph Leveque, MD, Vice President, US Medical - Oncology at Bristol-Myers Squibb
with Margaret Hamburg, MD, Commissioner at Food and Drug Administration (FDA)
To see the full agenda or to register for this event, please visit:
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO, The RPM Report, and "The Pink Sheet." For more information, visit: .
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including and , and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include , , , and , which enhance the productivity of science and health professionals, and the and , which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, employs 7,000 people worldwide. The company is part of , a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Mike Fergus
Elsevier Business Intelligence
908-748-1185
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.10.2013 - 13:59 Uhr
Sprache: Deutsch
News-ID 306813
Anzahl Zeichen: 0
contact information:
Town:
WASHINGTON, DC
Kategorie:
National
Diese Pressemitteilung wurde bisher 304 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Welcome to the Breakthrough Era! Join Us at FDA/CMS Summit to Explore the Emerging Public Policy Climate for Highly Effective Targeted Therapies"
steht unter der journalistisch-redaktionellen Verantwortung von
Elsevier Business Intelligence (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
